Expected Moves

Actual outcome: Bull · $9.52 at outcome

ACOG reported a quarterly loss of $0.4 per share, slightly below the estimate of $0.39, but highlighted a 71% sequential increase in revenue to $6 million from its Alzheimer's treatment ZUNVEYL. The stock remained flat, reflecting mixed sentiment due to the earnings miss but positive momentum from strong revenue growth and growing prescriber adoption.